おすすめの製品
アッセイ
99.9%
形状
foil
メーカー/製品名
Goodfellow 078-442-49
抵抗性
7.1 μΩ-cm, 0°C
L × W ×厚み
10 mm × 10 mm × 1.0 mm
bp
3900 °C (lit.)
mp
2310 °C (lit.)
密度
12.45 g/cm3 (lit.)
SMILES記法
[Ru]
InChI
1S/Ru
InChI Key
KJTLSVCANCCWHF-UHFFFAOYSA-N
類似した製品をお探しですか? 訪問 製品比較ガイド
詳細
For updated SDS information please visit www.goodfellow.com.
法的情報
Goodfellow製品
保管分類コード
13 - Non Combustible Solids
WGK
nwg
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
GF07844249-2EA:
GF07844249-1EA:
最新バージョンのいずれかを選択してください:
Chimia, 66(6), 386-388 (2012-08-09)
Certain ruthenium complexes are potent catalysts for atom transfer radical addition (ATRA) and cyclization (ATRC) reactions, in particular if they are used in conjunction with reducing agents such as magnesium. This short overview summarizes recent developments in this area with
Nitric oxide : biology and chemistry, 26(1), 38-53 (2011-12-20)
Nitric oxide plays an important role in various biological processes, such as neurotransmission, blood pressure control, immunological responses, and antioxidant action. The control of its local concentration, which is crucial for obtaining the desired effect, can be achieved with exogenous
Current medicinal chemistry, 17(31), 3643-3657 (2010-09-18)
The discovery of the involvement of nitric oxide (NO) in several physiological and pathophysiological processes launched a spectacular increase in studies in areas such as chemistry, biochemistry, and pharmacology. As a consequence, the development of NO donors or scavengers for
Chemical Society reviews, 41(8), 3179-3192 (2012-02-09)
In the last few decades, coordination complexes based on d(6) metal centres and polypyridyl ligand architectures been developed as structure- and site-specific reversible DNA binding agents. Due to their attractive photophysical properties, much of this research has focused on complexes
Metallomics : integrated biometal science, 1(6), 458-470 (2009-11-01)
Interest in Ru anticancer drugs has been growing rapidly since NAMI-A ((ImH(+))[Ru(III)Cl(4)(Im)(S-dmso)], where Im = imidazole and S-dmso = S-bound dimethylsulfoxide) or KP1019 ((IndH(+))[Ru(III)Cl(4)(Ind)(2)], where Ind = indazole) have successfully completed phase I clinical trials and an array of other
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)